Effects of diadenosine polyphosphates on systemic and regional hemodynamics in anesthetized rats.
Diadenosine polyphosphates (Ap4A, Ap5A, Ap6A) induce vasodilatation or vasoconstriction in various isolated vessels and influence central and peripheral hemodynamics. The influence of diadenosine polyphosphates on hemodynamics was studied in anesthetized rats in vivo. Mean arterial blood pressure (MABP) and heart rate (HR) measured in the carotid artery decreased with Ap4A, Ap5A, and Ap6A. Renal blood flow (RBF), femoral blood flow (FBF) and cardiac output (CO) were evaluated by an ultrasonic transit-time method. Renal superficial blood flow (RSBF) was measured by laser Doppler flowmetry. CO, RBF and RSBF were decreased initially by all three diadenosine polyphosphates. FBF was also slightly decreased. Total peripheral (TPR), renal (RVR) and femoral (FVR) vascular resistances were calculated. TPR was transiently increased by the dinucleotides following by a decrease. RVR and, to a lesser extent, FVR were also increased. These data show that diadenosine polyphosphates have effects on both the heart and the peripheral blood vessels. The effects on the heart and MABP were dominated by bradycardia and hypotension. In the kidney, diadenosine polyphosphates induced a predominant vascoconstriction. The effects on skeletal muscle blood flow were much smaller. Thus, the three diadenosine polyphosphates studied differ in the effects on heart and peripheral vessels.
Khattab
M
M
Department of Pharmacology, Faculty of Pharmacy, Cairo University, Egypt.
Hohage
H
H
Hollah
P
P
Rahn
K H
KH
Schlatter
E
E
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D015226:Dinucleoside Phosphates / Q000097:blood / Q000494:pharmacology*; D005263:Femoral Artery / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects*; D007668:Kidney / Q000098:blood supply / Q000502:physiology; D008297:Male; D009599:Nitroprusside / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000097:blood / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects; D015290:Second Messenger Systems; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000097:blood / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology
D015226:Dinucleoside Phosphates; D010975:Platelet Aggregation Inhibitors; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D009599:Nitroprusside; C012275:P(1),P(5)-di(adenosine-5'-)pentaphosphate; C020733:diadenosine tetraphosphate; C070070:diadenosine 5',5''''-P1,P6-hexaphosphate; D009638:Norepinephrine